Fascinating article in ScienceDaily from Ian Lipkin and research staff at Columbia University's Mailman School of Public Health. And timely too --- the trolls like to refer to Dr. Richt as a veterinarian -- instead he's on the cutting edge of human disease. 320,000 virus's in mammals? Sounds like plenty of work to go around for anti-viral drugs.
Sep. 3, 2013 — Scientists estimate that there is a minimum of 320,000 viruses in mammals awaiting discovery. Collecting evidence of these viruses, or even a majority of them, they say, could provide information critical to early detection and mitigation of disease outbreaks in humans. This undertaking would cost approximately $6.3 billion, or $1.4 billion if limited to 85% of total viral diversity -- a fraction of the economic impact of a major pandemic like SARS.
Close to 70% of emerging viral diseases such as HIV/AIDS, West Nile, Ebola, SARS, and influenza, are zoonoses -- infections of animals that cross into humans. Yet until now, there has been no good estimate of the actual number of viruses that exist in any wildlife species.
So HEB has two products that have been around for DECADES and one is to get excited about "animal testing"? It's animal testing, then on humans. Both which HEB's drugs have already done and it still isn't approved for anything at all.
If Dr. Richt does finally find a use for any of HEB's drugs, it will be 10+ years and 100 million dollars before it would get in front of the FDA. Heb doesn't have 10 years (Carter will be almost 90) or 100 million. Keep trying Hebmasterbator
Hemispherx has patents comprising its core intellectual property estate and a fully commercialized product (Alferon N Injection(R)), approved for sale in the U.S. and Argentina. The Company's Alferon N approval in Argentina includes the use of Alferon N Injection (under the brand name "Naturaferon") for use in any patients who fail, or become intolerant to recombinant interferon, including patients with chronic active hepatitis C infection. The Company wholly owns and exclusively operates a GMP certified manufacturing facility in the United States for commercial products.
A more systematic, multidisciplinary, and One Health framework is needed if we are to understand what drives and controls viral diversity and following that, what causes viruses to emerge as disease-causing pathogens."
Hey, isn't Dr. Richt the guy that heads up the One Health network????? And isn't Lipkin a partner in CEEZAD????